嗅覚神経芽細胞腫の小児および成人の自然史研究
Background:
Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can affect a person s sense of smell. Researchers want to better understand the health problems of people with ONB. This may help them design better treatment and supportive care studies.
Objective:
To better understand ONB-the course of the disease, tumor characteristics, response to treatments, and management of the treatment.
Eligibility:
People ages 3 years and older who have ONB. They must enroll in NIH studies #19-C-0016 and #18-DC-0051.
Design:
Participants will be screened with a medical history and medical record review.
Participants do not have to visit NIH.
Participants will give a blood sample. They will complete surveys to assess their emotional and physical wellbeing and needs. Leftover tissue from biopsies and surgeries will be collected.
Participants will take smell tests. They will smell items and answer questions about them.
Participants may take taste tests. They will get plastic taste strips that they will move around their mouth to determine the taste.
Participants may have a physical exam. Their performance status may be assessed.
Participants may give blood, saliva, urine, and nasal secretion samples.
Participants may have computed tomography and/or magnetic resonance imaging scans.
Participants may have one or more tumor biopsies.
Participants will talk to the research team about the results of their medical record/tests evaluation. The team will recommend how to best manage and treat their disease.
Participants may give samples and complete surveys every 12 months. Their medical records will be reviewed every year. They will be monitored for the rest of their life.
調査の概要
状態
詳細な説明
Background:
Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 cases per year in the United States).
ONB most frequently arises in adults aged 20-60 years. Pediatric ONB is particularly rare, with only small case series or multi-institutional studies reported. However, a Surveillance Epidemiology and End Results (SEER) study of 47 pediatric patients with intranasal malignancy reported ONB as the most frequent pediatric intranasal malignancy (28%).
Due to the location of ONB in the sinonasal tract and anterior skull base, the presenting symptoms are often non-specific, including nasal obstruction and epistaxis, thus patients often present at advanced stages. Furthermore, ONB has a propensity for local invasion and relatively high rates of distant spread most commonly to the neck, lungs, and bones.
Clinical management in adults is generally surgical with adjuvant radiation.
The natural history of pediatric and adult ONB is incompletely understood, and treatment options for recurrent or metastatic ONB are limited. The planned natural history study as part of the NCI POB Rare Tumor Patient Engagement Network (RTPEN) will allow for comprehensive evaluation and recommendations to these patients while longitudinally collecting clinical, epidemiologic, and biological data.
Objective:
To characterize the natural history of ONB including clinical presentation, family history, patterns of disease progression, response to current treatment methods, disease recurrence, and overall survival
Eligibility:
Participants of age >= 3 years old with histologically documented ONB.
Design:
This protocol is intended to characterize the natural history of olfactory neuroblastoma.
Participants will undergo a comprehensive study entry evaluation including acquisition of imaging of tumor sites.
Medical histories will be documented, and participants followed throughout the course of their disease, with particular attention to patterns of disease recurrence and progression, response to therapies, duration of responses, and patient reported outcomes. Specimens will be obtained longitudinally, when feasible, and tumor growth rates will also be assessed throughout the course of the disease, when feasible.
Blood and tumor samples may be obtained at study entry and while on study.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Marissa B Mallek, R.N.
- 電話番号:(240) 760-7498
- メール:marissa.mallek@nih.gov
研究連絡先のバックアップ
- 名前:Charalampos Floudas, M.D.
- 電話番号:(240) 474-1575
- メール:charalampos.floudas@nih.gov
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- 募集
- National Institutes of Health Clinical Center
-
コンタクト:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- 電話番号:888-624-1937
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with olfactory neuroblastoma.
説明
- INCLUSION CRITERIA:.
- Subjects with histologically documented olfactory neuroblastoma.
- Age >= 3 years old.
- Ability of subject to understand and the willingness to sign a written consent document
EXCLUSION CRITERIA:
Pregnant women are excluded from this study because of more than minimal risk activities (imaging studies with contrast, biopsies) pertaining to enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Cohort 1
Subjects with confirmed olfactory neuroblastoma. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Characterize the natural history of ONB
時間枠:duration of study
|
To characterize the natural history of ONB including clinical presentation, family history, patterns of disease progression, response to current treatment methods, disease recurrence, and overall survival. |
duration of study
|
協力者と研究者
捜査官
- 主任研究者:Charalampos Floudas, M.D.、National Cancer Institute (NCI)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 210009
- 21-C-0009
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
IPD 共有時間枠
Clinical data available during the study and indefinitely.@@@@@@@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD 共有アクセス基準
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。